Regulatory

Regulatory  ·  Weekly Digest - 10 January to 16 January 2026
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has included SHR-1826 in its list of breakthrough therapies for non-squamous non-small cell lung cancer with c-Met overexpression

Weekly Digest – January 2026 Weekly Digest – January 2026 12 January 2026: The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has included SHR-1826 in its list of breakthrough therapies for non-squamous non-small cell lung […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 10 January to 16 January 2026
SK Biopharm wins FDA approval for Phase 1 trial of alpha-emitter cancer therapy

Weekly Digest – January 2026 Weekly Digest – January 2026 12 January 2026: SK Biopharm wins FDA approval for Phase 1 trial of alpha-emitter cancer therapy SK Biopharm announced that it has received U.S. FDA approval for an investigational new […]

by Sandhya Ramalingam

Continue Reading